
Crescent Biopharma, Inc.: updates and filings
Price
$13.00
November 20, 2026Market cap $506M
What Ploutos Investor adds for Crescent Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Jan 29, 2027
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
November 2026
October 2026
July 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Results of operationsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 15, 2026Other material eventsForm8-K
- Sep 18, 2026Shares registered for employeesFormS-8
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 31, 2026FilingFormEFFECT
- Jul 30, 2026FilingFormPOS AM
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operationsForm8-K
- Jul 20, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 15, 2026Other material eventsForm8-K
- Jul 14, 2026Results of operationsForm8-K
- Jul 10, 2026FilingFormEFFECT
- Jul 1, 2026Shelf registration for future offeringsFormS-3
- Jun 22, 2026Quarterly report (amendment)for the period to Mar 31, 2026Form10-Q/A
- Jun 3, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Results of operationsForm8-K
- Apr 29, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 15, 2026 | 8-K | Other material events | Document |
| Sep 18, 2026 | S-8 | Shares registered for employees | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 31, 2026 | EFFECT | Filing | Document |
| Jul 30, 2026 | POS AM | Filing | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations | Document |
| Jul 20, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 15, 2026 | 8-K | Other material events | Document |
| Jul 14, 2026 | 8-K | Results of operations | Document |
| Jul 10, 2026 | EFFECT | Filing | Document |
| Jul 1, 2026 | S-3 | Shelf registration for future offerings | Document |
| Jun 22, 2026 | 10-Q/A | Quarterly report (amendment)for the period to Mar 31, 2026 | Document |
| Jun 3, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 10, 2003.
The full analysis
What do Crescent Biopharma's filings show?
The filings are where every one of Crescent Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.